INNV at a glance
InnovAge Holding Corp. (INNV, SEC CIK 1834376) filed its latest 10-K annual report on September 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 26, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), InnovAge Holding Corp. (INNV) reported revenue of $989.7 million (up 15.9% from FY2025) and a net loss of $2.5 million. Diluted EPS was -$0.02.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding InnovAge Holding Corp. (INNV) shares worth $75.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by DAMATO NICOLE on October 22, 2026 of 3,402 shares at $9.51 per share.
- In the last 90 days, INNV insiders reported 0 open-market purchases ($0) and 8 open-market sales ($226.9M) on Form 4, a net sale of $226.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $989.7M
- +15.9% vs prior year
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$226.9M
- 13F holders
- 23 funds
- $75.7M · −1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Business Overview
- Core business: All-inclusive, capitated healthcare delivery via PACE targeting high-cost, dual-eligible seniors to enable aging at home
- New emphasis on de novo centers launched in Florida (Tampa, Orlando) and joint ventures with Orlando Health and Tampa General Hospital in 2026
- Strategic shift: Increased focus on technology and data analytics investments to enhance care coordination and payor capabilities
- Quantitative: Served ~8,230 participants (largest US PACE provider), operating 20 centers across 6 states, with 2,500 employees (1,600+ clinical)
- Noteworthy: 2026 I-SAT participant satisfaction NPS of 52 vs national PACE average 59, demonstrating strong engagement despite growing complexity of participants
Risk Factors
- Regulatory risk: False Claims Act allegations with DOJ and Colorado AG; $37M accrual recorded Q4 FY26, investigation ongoing, may cause material losses or penalties
- Macroeconomic threat: Labor shortages and California SB 525 wage increases raised FY26 care costs; 70.2% revenue from CA and CO exposes to state budget cuts
- Operational risk: California PACE application pause (Nov 2025-Nov 2027) limits new center openings and expansions, restraining CA market growth
- Competitive risk: Medicare Advantage Special Needs Plans and ACOs pose competition for participants; expansion into new states faces competitors with stronger local presence
- Financial risk: $48.8M outstanding Term Loan A debt with restrictive covenants may constrain operational flexibility and increase refinancing risk
Management Discussion & Analysis
- Revenue $989.7M, up 15.9% YoY driven by $988.4M capitation revenue (16.0% increase, +$136.0M) from member growth and rate hikes
- Operating income $2.6M vs loss $(29.8)M; net loss $(0.7)M vs $(35.3)M; adjusted EBITDA margin 9.6% vs 4.0% driven by revenue growth and margin improvement
- Best segment PACE with Center-level Contribution Margin $227.8M, 23.0% of revenue vs $153.6M, 18.0% prior year; Senior Housing segment minimal, below reporting threshold
- Operating cash flow $64.7M, capex $12.3M, financing cash outflow $18.5M including share repurchases; debt $48.8M with $93.8M available under revolving credit
- FY27 risk from Medicaid rate reductions (e.g., Colorado) and California PACE moratorium; increasing care costs expected but partially offset by initiatives; management investing in growth and clinical value
AI summary of the INNV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $264.8M, up 12.1% YoY from $236.1M, driven by higher capitation rates and member months
- Net income margin 7.9% vs 3.2% YoY; Adjusted EBITDA margin 11.8% vs 7.5%
- Center-level Contribution Margin $63.6M, 24.0% of revenue vs $51.4M and 21.8% YoY
- Cash and equivalents $119.3M, up $21.4M; operating cash flow $28.7M vs $3.9M YoY
- Expected Medicaid rate pressures and higher provider costs in fiscal 2027, with Colorado rates decreasing retroactively
AI summary of the INNV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q1 fiscal 2026 results for the quarter ended September 30, 2026 announced by press release
- Exhibit 99.1 contains the financial results and related investor-relevant commentary
Item EX-99.1: Item EX-99.1
- Fiscal Q1 2027 revenue $264.8M, up 12.1% year over year, supported by census growth to approximately 8,420 participants
- Net income $20.9M, up from $7.7M, with margin expanding to 7.9% from 3.2%
Item 8.01: Other Events
- Selling shareholder sold 10,000,000 InnovAge shares at $9.25 each through an underwritten offering
- Company receives no proceeds, limiting balance-sheet benefit and signaling shareholder-level liquidity rather than corporate fundraising
Item 2.02: Results of Operations and Financial Condition
- Fiscal fourth-quarter and full-year results ended June 30, 2026 announced
- Press release issued September 8, 2026, with detailed financial results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FY2026 revenue $989.7M, up 15.9%, supported by census growth to approximately 8,230 participants
- Adjusted EBITDA $94.6M, up from $34.5M, with margin expanding to 9.6% from 4.0%
AI summaries of INNV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INNV
Don't miss the next INNV filing
- Alerts as it files. A push when INNV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INNV, by share count.
- Ask anything. An AI agent that reads every INNV filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DAMATO NICOLE | Sell | Oct 22, 2026 | 3,402 | $9.51 |
| Welsh, Carson, Anderson & Stowe XII, L.P. | Sell | Oct 21, 2026 | 1,500,000 | $9.25 |
| TCO GROUP HOLDINGS, L.P. | Sell | Oct 21, 2026 | 1,500,000 | $9.25 |
| IGNITE AGGREGATOR LP | Sell | Oct 21, 2026 | 1,500,000 | $9.25 |
| DAMATO NICOLE | Sell | Sep 25, 2026 | 23,814 | $8.70 |
| Welsh, Carson, Anderson & Stowe XII, L.P. | Sell | Sep 24, 2026 | 10,000,000 | - |
| TCO GROUP HOLDINGS, L.P. | Sell | Sep 24, 2026 | 10,000,000 | $9.25 |
| IGNITE AGGREGATOR LP | Sell | Sep 24, 2026 | 10,000,000 | $9.25 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | $763.9M | $853.7M | $989.7M |
| Gross Profit | - | $153.6M | $227.8M |
| Operating Income | - | -$29.8M | $2.6M |
| Net Income | - | -$30.3M | -$2.5M |
| Gross Margin | - | 18.0% | 23.0% |
| Op. Margin | - | -3.5% | 0.3% |
| Net Margin | - | -3.6% | -0.3% |
| Balance Sheet | |||
| Total Assets | - | $526.9M | $557.4M |
| Equity | - | $235.0M | $235.6M |
| ROE | - | -12.9% | -1.1% |
| Per Share | |||
| EPS | - | $-0.22 | $-0.02 |
| Cash Flow | |||
| Operating CF | - | $32.9M | $64.7M |
| CapEx | $7.9M | $6.3M | $14.3M |
Source: XBRL data in InnovAge Holding Corp. (INNV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate INNV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $75.7M |
| Q2 2026 | 24 | $58.6M |
| Q1 2026 | 24 | $33.6M |
| Q4 2025 | 20 | $19.1M |
| Q3 2025 | 17 | $18.1M |
| Q2 2025 | 19 | $12.8M |
| Q1 2025 | 14 | $6.7M |
| Q4 2024 | 9 | $9.3M |
- Millennium Management+663.8K (+446%)
- Goldman Sachs Group+450.6K (+207%)
- Vanguard Capital Management LLC+424.4K (+45%)
- Morgan Stanley+277.9K (+414%)
- Two Sigma Investments+106.9K (+93%)
- Renaissance Technologies LLC−35.2K (-14%)
- BlackRock−30.6K (-2%)
- Wells Fargo & Co−13.4K (-67%)
- Prudential Financial−10.5K (-8%)
- Citigroup−8.0K (-78%)
- Citadel Advisors LLC+1.63M
- Franklin Resources−10.3K
- FMR LLC (Fidelity)−4.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INNV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 10-K | Sep 9, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
Related Health Care companies
- DCGO · DocGo Inc.Services-Health Services
- WGS · GeneDx Holdings Corp.Services-Health Services
- LFST · LifeStance Health Group, Inc.Services-Health Services
- OMDA · Omada Health, Inc.Services-Health Services
- PNTG · Pennant Group, Inc.Services-Health Services
- PRVA · Privia Health Group, Inc.Services-Health Services
- SRTA · Strata Critical Medical, Inc.Services-Health Services
- TALK · Talkspace, Inc.Services-Health Services
INNV SEC filings: frequently asked questions
Are INNV insiders buying or selling?
In the last 90 days, InnovAge Holding Corp. (INNV) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $226.9 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold INNV stock?
As of September 30, 2026, the largest InnovAge Holding Corp. (INNV) holders among the 13F filers tracked by SignalX were Citadel Advisors LLC ($14.3 million), BlackRock ($12.8 million), Vanguard Capital Management LLC ($12.0 million), Millennium Management ($7.2 million), Goldman Sachs Group ($5.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INNV's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), InnovAge Holding Corp. (INNV) reported revenue of $989.7 million (up 15.9% from FY2025) and a net loss of $2.5 million. Diluted EPS was -$0.02. The figures come from the XBRL data in the 10-K.
What are the main risks in INNV's latest 10-K?
In the 10-K filed September 9, 2026, InnovAge Holding Corp. (INNV) flagged: Regulatory risk: False Claims Act allegations with DOJ and Colorado AG; $37M accrual recorded Q4 FY26, investigation ongoing, may cause material losses or penalties. Macroeconomic threat: Labor shortages and California SB 525 wage increases raised FY26 care costs; 70.2% revenue from CA and CO exposes to state budget cuts. (AI summary of the Risk Factors section.)
What did INNV report in its latest 8-K?
InnovAge Holding Corp. (INNV) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 fiscal 2026 results for the quarter ended September 30, 2026 announced by press release.
What are the latest INNV SEC filings?
InnovAge Holding Corp. (INNV) filed its latest 10-K annual report on September 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 26, 2026.
What is INNV's SEC CIK number?
InnovAge Holding Corp. (INNV)'s SEC Central Index Key (CIK) is 1834376. EDGAR lists every INNV filing under that number.
Ask anything about INNV
The research agent reads INNV's filings, financials, insider trades and 13F holders, then answers with sources.